Abstract

Progress Report P&F 6 - Identification of Immune Targets in Psoriatic Arthritis PI: Mark Soloski, Ph.D. We propose a series of studies aimed at identifying candidate molecular species targeted for immune recognition in Psoriatic Arthritis. In this study, we propose to: 1. Screen serum from Psoriatic Arthritis (PsA) patients and normal controls for the presence of antibodies reactive toward cellular protein species. 2. Identify and characterize the molecular species targeted for recognition by autoantiboclies in PsA using a proteomics based approach. In the initial phases of this study we have collected and archived serum, PMBCs and affected and unaffected skin samples from 43 normal and 23 PsA patients. In addition we have established a western blotting approach that we will employ to help identify proteins species targeted for recognition by PsA autoimmune serum. To date we have successfully tested keratinocyte cellular extracts with this western blotting approach for the presence of autoantigens targeted in SLE (U160k and PARP) and found the approach sensitive and reliable. We are currently generating cell extracts for a range of cell types which will be utilized in this approach.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053503-05
Application #
8121546
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$11,224
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

McGrath-Morrow, Sharon A; Ndeh, Roland; Helmin, Kathryn A et al. (2018) DNA methylation regulates the neonatal CD4+ T-cell response to pneumonia in mice. J Biol Chem 293:11772-11783
Shi, Jing; Darrah, Erika; Sims, Gary P et al. (2018) Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis. Ann Rheum Dis 77:141-148
Lee, Yvonne C; Bingham 3rd, Clifton O; Edwards, Robert R et al. (2018) Association Between Pain Sensitization and Disease Activity in Patients With Rheumatoid Arthritis: A Cross-Sectional Study. Arthritis Care Res (Hoboken) 70:197-204
Wohlfahrt, Alyssa; Bingham 3rd, Clifton O; Marder, Wendy et al. (2018) Responsiveness of Patient Reported Outcomes Measurement Information System (PROMIS) Measures in RA Patients Starting or Switching a DMARD. Arthritis Care Res (Hoboken) :
Leung, Ying Ying; Ogdie, Alexis; Orbai, Ana-Maria et al. (2018) Classification and Outcome Measures for Psoriatic Arthritis. Front Med (Lausanne) 5:246
Cohen, Ezra M; Edwards, Robert R; Bingham 3rd, Clifton O et al. (2018) Pain and Catastrophizing in Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study. J Clin Rheumatol :
Bartlett, S J; Gutierrez, A K; Butanis, A et al. (2018) Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Qual Life Res 27:2443-2451
Darrah, Erika; Yu, Fang; Cappelli, Laura C et al. (2018) Association of baseline peptidylarginine deiminase 4 autoantibodies with favorable response to treatment escalation in rheumatoid arthritis. Arthritis Rheumatol :
Cappelli, Laura C; Konig, Maximilian F; Gelber, Allan C et al. (2018) Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. Arthritis Res Ther 20:59
Igusa, Takeru; Hummers, Laura K; Visvanathan, Kala et al. (2018) Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer. Ann Rheum Dis 77:1179-1186

Showing the most recent 10 out of 125 publications